

PATENT
[4020.000400]4020.000499

J1036 U.S. PTO
09/826396
04/03/01

HL

**MARKED COPY OF SUBSTITUTE SPECIFICATION
(SPECIFICATION, ABSTRACT)**

for

MOLECULAR PROBES AND MODULATORS FOR PI-PLC AND PI 3-KINASE

by

Rajindra Aneja

MOLECULAR PROBES AND MODULATORS FOR PI-PLC AND PI 3-KINASE

BACKGROUND OF THE INVENTION

The present application claims priority to co-pending application Serial No. 08/872,222,
5 filed June 10, 1997; which claims priority to provisional application Serial No. 60/019,651, filed
June 11, 1996. This invention was partially made with funds provided by the Department of
Health and Human Services under Grant No. NIH-GM51138. Accordingly, the United States
Government has certain rights in this invention.

This invention is concerned with certain structural and stereochemical analogues of the
10 phosphoinositide group of cellular lipids, novel approaches for their preparation by synthesis and
key starting materials and intermediates of these approaches. The phosphoinositides comprising
1D-1-(1',2'-di-*O*-fattyacyl-*sn*-glycero-3'-phospho)-*myo*-inositols or phosphatidylinositol (PtdIns)
and its mono- and poly-phosphate derivatives are key participants in the intracellular signaling
cascade which is generated in response to stimulation of certain cell surface receptors by many
15 agonists. Biosynthetic and metabolic transformations of the phosphoinositides are implicated in
initiating, sustaining and regulating this signal cascade in an agonist and tissue specific manner.
These lipid transformations are catalyzed by several families of enzymes including the
phosphatidylinositol-specific phospholipase C (PI-PLC) and the phosphatidylinositol 3-kinase (PI
3-kinase). Stimulated hydrolysis of phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P₂), the
20 substrate preferred by the mammalian PI-PLC, is representative. This hydrolysis rapidly and
simultaneously generates inositol-1,4,5-trisphosphate (IP₃) and *sn*-1,2-diacylglycerol (DAG).
Both IP₃ and DAG are second messengers respectively inducing Ca⁺⁺ mobilization from
intracellular stores and protein kinase C (PKC) activation and are implicated in many
physiological responses including mitogenesis (Berridge, 1984; Nishizuka, 1983). Specific PI-
25 PLC enzymes function also in releasing membrane-anchored proteins using glycosyl-PtdIns as the
anchoring ligand. PI 3-kinase specifically associates with and is phosphorylated by activated
growth factor receptors and oncoproteins which manifest protein-tyrosine kinase activity
(Whitman et al, 1988; Auger et al, 1989). It phosphorylates PtdIns(4,5)P₂ specifically at the D-3
hydroxyl to produce phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P₃) which is the
30 putative novel and critical second messenger of growth signals (Auger et al, 1989; Carpenter and
Cantley, 1990; Coughlin et al, 1989; Majerus, 1992). A complex role for PI 3-kinase and its

products, the 3-phosphorylated phosphoinositides (3PPI), is emerging in the control of cell division and growth (Carpenter and Cantley, 1996). Additionally a role is seen for PI 3-kinase in transient actin polymerization and association between actin and cellular cytoskeletal elements, and a possible connection between this and the role in cell growth. Thus there is tremendous current interest in elucidating the structure, biochemical behavior, and physiological roles of the various isoforms of these key enzymes and in tracing the downstream targets of the products of their action on the phosphoinositides. Probes and modulators incorporating the core PtdIns(4,5)₂ structure as provided by the present invention are required for these multifarious ongoing research investigations.

Endogenous IP₃ is dephosphorylated and is reutilized with DAG for the resynthesis of PtdIns, the PtdIns is rephosphorylated to PtdIns-phosphates, and the latter are converted back to PtdIns by the action of PtdIns-phosphate phosphatases, in the overall PtdIns metabolic cycle. Exogenous inositols and PtdIns, including structurally modified analogues such as those disclosed in Kozikowski (U.S. Pat. No. 5,053,399), Kozikowski et al (U.S. Pat. No. 5,227,508), and, Yang et al (U.S. Pat. No. 4,515,722) are incorporated into the PtdIns cycle and ostensibly into the PtdIns-phosphate pool. The characterization of the biosynthetic PtdIns-phosphates produced from the aforementioned modified exogenous inositols and PtdIns derivatives requires the corresponding modified-PtdIns(4,5)P₂ and related derivatives as reference reagents. These reference reagents are provided by the present invention.

In the prior art (Yang et al, U.S. Pat. No. 4,515,722) synthesized 2-modified analogues of PtdIns and found these to be useful antiinflammatory/analgesic agents. These analogues all incorporated DL-inositol moieties and the preferred lipid moiety was 1-(3',4'-acyloxybutylphosphonyl. The same biological activity was also claimed for unspecified PtdIns-phosphate derivatives but no application as a research reagent was disclosed.

Several phosphoinositide analogues are known in the prior art relevant to the present invention. The fluorescent 1-pyrenebutyl *myo*-inositol-1-phosphate and the chromogenic 4-nitrophenyl *myo*-inositol-1-phosphate have been described as reagents for the assay of bacterial PI-PLC (Hendrickson et al, 1992; Shashidhar et al, 1991) but are poor substrates and considered to be inadequate reagents (Bruzik and Tsai, 1994). The preparation of a nanomolar quantity of a pyrene-labelled PtdIns(4,5)P₂ from the corresponding pyrene-labelled PtdIns by successive phosphorylations at 4-O and 5-O by partially purified PtdIns 4-kinase and PI 5-kinase has been

reported also (Gadella et al, 1990) but the required enzyme reagents and method of preparation are not easily accessible. Synthetic PtdIns(4,5)P₂ labelled with photoactive *p*-benzoyldihydrocinnamoyl and related reporter groups covalently attached to either the 1'-acyloxy or the 1-phosphate have been reported recently (Gu and Prestwich, 1996; Chen et al, 1996).

5 These analogues are broadly similar, but attachment of the reporter group at 1-phosphate creates a 1-phosphotriester analogue and thereby destroys the core 1-phosphodiester function which is an essential structural feature of PtdIns(4,5)P₂ and all phosphoinositide substrate of PI-PLC.

10 It is considered that a sufficient range of appropriate biochemical probes and modulators of these enzymes are not available (Bruzik and Tsai, 1994). Therefore, an objective of the present invention is to provide substrate analogues as structure/mechanism-based probes and modulators suitable for research studies on PI-PLC, PI 3-kinase and related enzyme families. Additional objectives are to provide novel approaches for their preparation by synthesis and key starting materials and intermediates of these approaches.

15 SUMMARY OF THE INVENTION

This invention comprises several synthetic analogues of the preferred phosphoinositide substrates of the mammalian PI-PLC and PI 3-kinase enzyme families, exemplified by PtdIns(4,5)P₂, which retain the core structural requirements for efficient bonding and catalysis, but
20 in which the 2-OH is rendered non-nucleophilic by derivatization or replacement exemplified by 2-OAc and 2-deoxyfluoro respectively, and, which may additionally contain photoaffinity, fluorescent, spin, other reporter groups, and conjugands for linking to polymer, chromatographic matrix, or gold surfaces are incorporated in the fatty acyl or inositol residues as shown in structure.

Thus, the invention provides substrate analogues as structure/mechanism-based probes and
25 modulators suitable for research studies on PI-PLC, PI 3-kinase and related enzyme families. Additionally, it provides novel approaches for their preparation by synthesis, and key starting materials and intermediates of these approaches.

A BRIEF DESCRIPTION OF THE DRAWINGS


FIG 1. Scheme I: Synthesis of 1D-3,6-di-*O*-benzyl-2-deoxyfluoro-*myo*-inositol-4,5-bis(dibenzylphosphate) **10**.

5 FIG 2. Scheme II: Synthesis of 1,2-di-*O*-hexanoyl-*sn*-glycero-3-phosphoric acid (**15**) and 1-*O*-hexanoyl-2-*O*-(ω -Cbz-aminobutanoyl)-*sn*-glycero-3-phosphoric acid (**18**).

DETAILED DESCRIPTION OF THE INVENTION

10 Phosphatidyl-*myo*-inositol-4,5-bisphosphate (PtdIns(4,5)P₂) is a vital participant in intracellular signalling and allied processes, functioning as the preferred substrate of the mammalian phosphoinositide-specific phospholipase C (PI-PLC) and phosphoinositide 3-kinase (PI 3-kinase) enzymes, and, as allosteric activating factor of cellular regulatory proteins with and without pleckstrin homology domains.

15 In one embodiment, this invention comprises several synthetic analogues of PtdIns(4,5)P₂ (**1**, X=OH, R¹, R² = Alkyl-C=O) incorporating one or more of the following modifying structural features: (i) the 2-OH is rendered non-nucleophilic by derivatization or replacement exemplified by 2-OAc and 2-deoxyfluoro respectively, and (ii) photoaffinity, fluorescent, spin, other reporter groups, and conjugands for linking to polymer, chromatographic matrix, or gold surfaces are
20 incorporated in the fatty acyl or inositol residues as shown in structure **2**.



1. $X=OH$
 $R^1, R^2=Alkyl-C=O$
2. $X=F, H, OAc, OAllyl,$
 $OCH_2CH=O, OMe, etc. or OH$
 $R^1, R^2=Alkyl-C=O,$
 $(w-NH_2)-Alkyl-C=O,$
 $Alkyl, Reporter Groups, etc.$

5

These analogues have utility as research reagents as structure- and mechanism-based competitive inhibitors of the mammalian PI-PLC, applicable *inter alia* as comparative probes of enzyme-action and protein-binding in PI-PLC, as novel substrate analogues of PI 3-kinase, and general probes of PtdIns(4,5)P₂-binding to cellular regulatory proteins. In the prior art, deoxyfluoro-inositols (Kozikowski et al, U.S. Pat. No. 5,053,399), and deoxyfluoro-phosphatidylinositols (Yang et al, U.S. Pat. No. 4,515,722; Kozikowski et al, U.S. Pat. No. 5,227,508) have been described. These are being developed as therapeutic agents and their metabolic products must be identified. The analogues disclosed in the present invention are likely metabolic products of the aforementioned prior art therapeutics and therefore have utility as critical reference materials in analyses for establishing the presence or absence of such metabolic products. Several studies have provided information on the structural features of the substrate which are essential for PI-PLC enzyme activity. Most of the early findings were obtained with PI-PLC from bacterial sources although identical conclusions are emerging for the guinea pig uterus PI-PLC and the cloned isoforms. The consensus view has developed that the inositol-1-phosphate residue is required for substrate recognition as well as catalytic action. The presence of the free 2-OH is essential for catalytic action. Nucleophilic attack by this OH on the 1-phosphate phosphorus leads to the inositol-1:2cyclic-phosphates which are the diagnostic products of bacterial PI-PLC action (Lin et al, 1990; Volwerk et al, 1990). Binding to a lipid bilayer or equivalent lipid aggregate containing the substrate is essential for high activity. The crystal structure of the PI-PLC from *Bacillus cereus* in complex with its hydrolysis product, that is *myo*-inositol, has been solved to 2.6 Å (Heinz et al, 1995). This suggests that His32 acts as general base, accepting a proton from the *myo*-inositol 2-OH of PtdIns. Nucleophilic attack by the deprotonated 2-O on the phosphatidyl phosphorus results in a 5-cyclic phosphate and cleavage of DAG. Crystal structure of a mammalian PI-PLC δ 1 deletion mutant in complex with its hydrolysis

product, that is IP₃, has been determined (Essen et al, 1996; Grobler et al, 1996), and the complexes with Ins(1:2cyc)P and its 2-methylene analogue of have been studied (Essen et al, 1997). The data suggest a need and a mechanism for membrane attachment and for Ca²⁺-dependent hydrolysis of PtdIns(4,5)P₂. In the proposed reaction mechanism, the 2-OH group is deprotonated in the first step by an internal general base, followed by nucleophilic attack on the 1-phospho group and release of DAG.

Another embodiment of this invention comprises two complementary strategies for syntheses illustrated for 2-deoxyfluoro and 2-OAc type analogues respectively. The approach for synthesis of the 2-deoxyfluoro PtdIns(4,5)P₂ (2, X=F) and analogues involves the preparation of (i) optically resolved *O*-protected *myo*-inositol-4,5-bisphosphate with a free 1-OH and (ii) 1,2-di-*O*-fattyacyl-*sn*-glycero-3-phosphoric acid (*sn*-3-phosphatidic acid), as inositol and lipid synthons respectively, (iii) coupling of the inositol 1-OH and the lipid phosphoric acid by phosphodiester condensation, and (iv) deprotection of the condensation product to obtain the target PtdIns(4,5)P₂ analogue. This approach is suitable for other analogues also including the 2-OAlkyl types. The 2-OCOR types illustrated by 2-OAc (2, X=OAc) are best prepared from a synthetic PtdIns(4,5)P₂ derivative in which the 3, 4, 5, and 6-OH or derived phosphates selectively carry temporary protecting groups and the unprotected 2-OH is rendered non-nucleophilic by derivatization to an ester or equivalent, followed by removal of the temporary protecting groups.

In yet another embodiment of this invention, the synthetic 2-modified analogues of PtdIns(4,5)P₂ and corresponding analogues lacking the 2-modification (2, X=OH) are offered as matched pairs.

Yet another embodiment of the invention comprises derivatives of PtdIns(4)P, and PtdIns(3)P series analogous to the PtdIns(4,5) series above.

The key inositol synthon for the 2-deoxyfluoro series was prepared from 1D-3,6-di-*O*-benzyl-1,2:4,5-dicyclohexylidene-*myo*-inositol 3 (Aneja et al, 1995) as outlined in Scheme I, FIG 1. The two 2-deoxyfluoro epimers produced by the DAST reaction were separated by HPLC and the 2-epimer being the 2-deoxyfluoro-*scyllo*-inositol analogue was [themajor] the major product.

The synthesis of 1,2-di-*O*-hexanoyl-*sn*-glycero-3-phosphoric acid (15) and 1-*O*-hexanoyl-2-*O*-(ω -Cbz-aminobutanoyl)-*sn*-glycero-3-phosphoric acid (18), outlined in Scheme II, FIG 2,

illustrates the general approach to *sn*-3-phosphatidic acids is adapted from literature methods (Aneja, 1974).

The inositol and lipid synthons were coupled using triisopropylbenzene-sulfonyl chloride in anhydrous pyridine at R.T (Aneja et al, 1997). The product was subjected to Pd-C catalyzed
5 hydrogenolysis to remove the benzyl ether-ester protecting groups to obtain **2** (example, X=F, $R^1=R^2=C_{15}H_{31}CO$).

The structure of the inositol synthon **10** may be varied by replacing reaction of **6** with DAST in Scheme I step d by other reagents to produce 2-deoxy, oxo, *O*-acyl, *O*-alkyl, deoxyhalo or deoxydihalo analogues of the inositol synthon **10**. Benzylation of **6** yielded the
10 2-*O*-benzyl analogue **11** of **7**. Subsequent transformations exactly as in Scheme I gave 1D-2,3,6-tri-*O*-benzyl-*myo*-inositol-4,5-bis(dibenzylphosphate) **12**, the key inositol synthon for PtdIns(4,5)P₂ unmodified in the inositol residue.

With **18** as the *sn*-3-phosphatidic acid, the products of condensation-hydrogenolysis yielded 1-*O*-hexanoyl-2-*O*-(aminobutanoyl)-*sn*-3-phosphatidyl-based PtdIns(4,5)P₂s; reaction
15 of the primary amino group in these with "activated" reporter ligands gave the labelled analogues; for example reaction with *N*-hydroxysuccinimidyl-4-azidosalicylic acid gave the 4-azidosalicyl photoaffinity-labelled analogue.

In the second strategy for synthesis, 1D-(1,2-dihexadecanoyl-*sn*-glycero-3-phospho)-*myo*-inositol-3,6-di-*O*-benzyl-4,5-bis(dibenzylphosphate) was prepared by the method
20 reported for the dihexanoyl derivative (Toker et al. 1994). On treatment with an OH acylating reagent, for instance AC₂O-DCC-DMAP, it gave the 2-*O*-acetyl derivative, which was hydrogenolyzed to the 2-OAc analogue of PtdIns(4,5)P₂ (**2**, X=OAc, $R^1=R^2=C_{15}H_{31}CO$). The short-chain acyloxy derivatives are prone to non-specific chemical hydrolysis.

The strategies for synthesis may be adapted for analogues incorporating reporter
25 groups linked to the inositol residue in PtdIns(4,5)P₂s, for instance, by employing the 6-*O*-di-*N*-benzylaminoalkyl analogue of **3** as the starting material.

The utility of the key intermediates is reflected in the synthesis of the target PtdIns-phosphate analogues. The condensation products of the *sn*-3-phosphatidic acids and the optically resolved *O*-protected *myo*-inositol-4,5-bisphosphate with an additional free hydroxyl
30 are particularly useful for incorporating other types of labels, such as radioactive or stable isotope based groups.

The action of PI-PLC on PtdIns(4,5)P₂ produces IP₃ and DAG. Ostensibly this involves intramolecular nucleophilic attack on the 1-phosphodiester by the 2-OH (Essen et al, 1996). The 2-modified analogues of PtdIns(4,5)P₂ of the present invention preclude the intramolecular nucleophilic action. As the core PtdIns(4,5)P₂ structure is retained, efficient
5 interaction with the catalytic and allosteric binding sites results. Additional design and performance features may be incorporated for special applications, as in 1D-1- (1,2-di-*O*-*n*-butyl-*sn*-glycero-3-phospho)-2-deoxyfluoro-*scyllo*-inositol-4,5-bisphosphate prepared as a water-soluble analogue, stable to non-specific chemical hydrolysis, and useful for the preparation of co-crystallizates with PI-PLC isozymes for X-ray crystal structure analysis.

10 For use as analytical research reagents, the behavior of the 2-modified PtdIns(4,5)P₂ analogues in analytical chromatography was established. Thin layer chromatography is carried out preferably on silicagel layers with organic binder and impregnated with potassium oxalate and EDTA as scavengers for adventitious silica. These thin layer plates can be prepared from commercial TLC plates, preferably Cat. No. 47031, Uniplate from Analtech
15 Inc., Newark, NJ by dipping briefly in a solution of K⁺ oxalate (1%) and Na₄ EDTA (0.6%) in methanol-water (3:2) followed by air-drying for 24 Hr. The plates are spotted with the analogue (1 to 10 mg) in solvent (CHCl₃-CH₃OH-H₂O, 2:1:0.2), development with eluant CHCl₃-CH₃OH-28% NH₄OH-H₂O (2:2:1:1) at room temperature, and, visualization with I₂ vapor or other appropriate reagent. The R_f of unmodified PtdIns(4,5)P₂ is ca. 0.5, for
20 analogues with ω-aminoalkyl residues the R_f is in the range 0.2 to 0.3, and the presence of 2-deoxyfluoro substituent raises the R_f by ca. 0.05 to 0.1 compared with the 2-OH series. The TLC conditions can be translated into protocols for liquid chromatography including high performance liquid chromatography (HPLC) by techniques which are well known to practitioners of chromatographic separation.

25 For co-crystallization with PI-PLC isozymes, the water soluble 2-deoxyfluoro dibutylether PtdIns(4,5)P₂ analogue may be added as a solution in buffer to the enzyme solution. Other protocols may be applied to suit individual experiments.

The invention has been delineated with reference to certain specific and preferred embodiments and methods. However, it is stated that many modifications and variations may
30 be made while remaining within the scope and spirit of the invention.

All referenced patents and publications are incorporated herein by citation.

EXAMPLES

1D-3,6-Di-*O*-benzyl-*myo*-inositol

1D-3,6-di-*O*-benzyl-1,2:4,5-di-*O*-cyclohexylidene-*myo*-inositol (5.0g, 0.0096mol),
5 prepared by a literature procedure (Aneja et al, Tetrahedron Asymmetry (1995) 6, 17-18)
was dissolved in 60 ml HOAc-H₂O (9:1) and heated at 95-100°C for 1 hr. The solution
was evaporated to dryness under reduced pressure and the residue co-evaporated with
H₂O, CHCl₃ and CH₃OH to dryness. The crude residue of virtually pure 1D-3,6-di-*O*-
benzyl-*myo*-inositol was used without purification: $[\alpha]_{589} +11.76^{\circ}$ (c 1.9, CHCl₃-CH₃OH
10 1:1). MALDI TDF MS *m/z* 361, ¹H NMR (300 MHz, CDOD₃) δ ppm 3.205 (d, 1H),
3.235 (d, 1H), 3.41 (d, 1H), 3.445 (d, 1H), 3.586-3.661 (q or dd) 3.71-3.90 (ψ t, J 9.7 and
9.7 Hz), 4.02-4.18 (ψ t, J 2.69 and 2.14 Hz), 4.62-4.75 (q, 4H), 7.14-7.62 (m 10 H).

1D-3,6-Di-*O*-benzyl-4,5-*O*-cyclohexylidene-*myo*-inositol

15 To a solution of 1D-3,6-di-*O*-benzyl-*myo*-inositol (4.1g, 0.011 mol) and
cyclohexanone dimethylketal 8 ml (0.05 mol) in dry DMSO (20ml), p-toluene sulphonic
acid monohydrate (pTSA) (35 mg) was added. The mixture was evacuated at 40-42°C
(red. pressure) for 5 hr. The solution was neutralized with saturated NaHCO₃ solution
and left at 0-5°C overnight. The products were extracted with ethyl acetate, organic layer
20 was dried over Na₂SO₄ and solvent evaporated. Resulting glassy material was triturated
with CH₂Cl₂ which dissolved the cyclohexylidene derivatives and the mixture was filtered
to remove the insoluble starting material (1.1g). TLC (CH₂Cl₂-ethyl acetate 1:1) of the
solution showed 1D-3,6-di-*O*-benzyl-1,2:4,5-*O*-cyclohexylidene-*myo*-inositol (*R_f*=0.9), a
major product (*R_f*=0.75), another product (*R_f*=0.55) and trace of the starting
25 material (*R_f*=0.2). The CH₂Cl₂ soluble material chromatographed on Silicagel 60 Å in
ethyl acetate-CH₂Cl₂ (1:4) gave the dicyclohexylidene derivative (0.150g) and then the
1D-3,6-di-*O*-benzyl-4,5-*O*-cyclohexylidene-*myo*-inositol (2.27g, 65%). Further elution
with the same solvent in ratio 1:2 gave 1D-3,6-di-*O*-benzyl-1,2-*O*-cyclohexylidene-*myo*-
inositol (Aneja et al, loc. cit.) (0.450 g, 13 %). $[\alpha]_{589} -33.2^{\circ}$ (c 1.3, CHCl₃); MALDI TDF
30 MS *m/z* 462.54, calc. 463.22 (M+Na)⁺, ¹H NMR (300MHz, CDCl₃) δ ppm 1.44-1.85

(br,10H), 2.66(m,2H), 3.38(t, J 9.66 and 9.67, 1H), 3.54-3.61(m, 2H), 3.81(t, J 8.6 and 9.7, 1H), 4.05(t, J 9.67 and 9.67, 1H), 4.21(ψt, 1H), 4.72(d, 2H), 4.95(q, 2H), 7.26-7.44 (m, 10H).

5 1D-3,6-Di-*O*-benzyl-4,5-*O*-cyclohexylidene-1-(*p*-methoxybenzyl)-*myo*-inositol

A mixture of 1D-3,6-di-*O*-benzyl-4,5-*O*-cyclohexylidene-*myo*-inositol (2.35g, 0.0053 mol), Bu₂SnO (1.33g, 0.0053 mol) and toluene (70 ml) was stirred under reflux with a Dean-Stark apparatus for azeotropic removal of the water for 2 hrs and then
10 evaporated to dryness under reduced pressure. To the residue was added DMF (40 ml), CsF (2.43 g, 0.016 mol) and 4-methoxybenzyl chloride (1.2 ml, 0.0088 mol) at 0-5°C. The reaction mixture was warmed and stirred at 40°C for 2 hrs and 1 hr at 60°C. The solution was cooled to r.t. and diluted with 100 ml CH₂Cl₂, washed with water, dried over Na₂SO₄ and concentrated. The crude product was chromatographed on Silicagel 60Å
15 using gradient elution with CH₂Cl₂-acetone (99:1 to 95:5) producing 1D-3,6-di-*O*-benzyl-4,5-*O*-cyclohexylidene-1-(*p*-methoxybenzyl)-*myo*-inositol, 2.37g (79 %): [α]_D²⁵ -12.03° (c 1.11, CHCl₃) HMRS FAB⁺ m/z 583.52, calc. (M+Na)⁺ 583.277, ¹H NMR (300MHz, CDCl₃) δppm 1.40-1.83 (br,10H), 2.64 (br,1H), 3.28-3.46 (m,2H), 3.48-3.63 (dd or q 1H), 3.75-3.89 (s,3H), 3.96 (ψt, J 8.59 and 9.67, 1H), 4.05-4.27 (m 2H), 4.55-
20 5.08 (m, 6H), 6.74-7.00 (m, 2H), 7.13-7.58 (m, 12H).

1D-3,6-Di-*O*-benzyl-2-deoxy-fluoro-4,5-*O*-cyclohexylidene-1-*O*-(*p*-[methoxybenzyl)-*myo*-inositol] methoxybenzyl)-*myo*/scyllo-inositol

To 1D-3,6-di-*O*-benzyl-4,5-*O*-cyclohexylidene-1-(*p*-methoxybenzyl)-*myo*-inositol
25 (0.9857g, 0.00176 mol) in 25 ml toluene under nitrogen atmosphere and at r.t. was added diethylaminosulphur trifluoride (0.35 ml, 0.0026 mol). The reaction mixture was stirred at r.t. for 1 hr and then the temperature was raised to 60°C for 4 hr. After cooling down to r.t. 50 ml of sat. NaHCO₃ solution were added. The mixture was extracted with 3x50 ml ethyl acetate and the extract was washed with 2x30 ml sat. NaCl solution. The
30 organic layer was dried over K₂CO₃, filtered and concentrated to a dark yellow syrup.

Column chromatography on Silicagel 60Å using gradient elution with hexane-CH₂Cl₂-ethyl acetate (95:4:1 to 50:25:25) gave pure 1D-3,6-di-*O*-benzyl-2-deoxy-fluoro-4,5-*O*-cycloxyldiene-1-*O*-(*p*-methoxybenzyl)-[*myo*-inositol] *myo/scyllo*-inositol; 0.5894 g (60%): [α]₅₈₉ -20.46° (c 0.5, CHCl₃) MALDI TDF MS *m/z* 587.19; calc. (M+Na)⁺ 586;

5 ¹H NMR (300 MHz, CDCl₃) δ ppm 1.2-1.9 (br, 10H), 3.4-3.6 (m, 2H), 3.6-3.7 (m, 1H), 3.7-3.8 (m, 1H), 3.8 (s, 3H), 4.47-4.57 (t, *J* 8.6 and 8.05, 1H), 4.6-5.00 (m, 6H), 6.8-7.00 (m, 2H), 7.15-7.51 (m, 12H).

1D-3,6-Di-*O*-benzyl-2-deoxy-fluoro-1-*O*-(*p*-methoxybenzyl)

10 [-*myo*-inositol] *myo/scyllo*-inositol

To a solution of 1D-3,6-di-*O*-benzyl-2-deoxy-fluoro-4,5-*O*-cycloxyldiene-1-*O*-(*p*-methoxybenzyl)-[*myo*-inositol] *myo/scyllo*-inositol (0.566 g, 1.007 mmol) and ethylene glycol (0.11 ml, 1.9 mmol) in 6 ml CH₂Cl₂-hexane (2:1), 12 mg of *p*-toluenesulphonic acid monohydrate was added. Reaction mixture was stirred at r.t. for 1 hr, then neutralized
15 with 15 μ l triethyl amine and 1 ml sat. NaHCO₃ solution. The product was extracted with 3x5 ml CH₂Cl₂. Organic layer was dried over Na₂SO₄ and concentrated. Chromatography on Silicagel 60Å using CHCl₃ as eluent gave pure 1D-3,6-di-*O*-benzyl-2-deoxy-fluoro-1-*O*-(*p*-methoxybenzyl)-[*myo*-inositol] *myo/scyllo*-inositol: 449.4 mg (92.6%). [α]₅₈₉ +9.0° (c 1.0, CHCl₃) MALDI TDF MS ¹H NMR (300 MHz, CDCl₃) δ ppm 2.6 (d, 2H),
20 3.35 (t, 2H), 3.45 (m, 2H), 3.65 (m, 1H), 3.83 (s, 3H), 4.4-4.6 (ψ t, *J* 2.7 and 6.44, 1H), 4.62-4.85 (m, 4H), 4.87-5.00 (dd, 2H), 6.75-7.00 (d, 2H), 7.18-7.60 (m, 12H).

1D-3,6-Di-*O*-benzyl-2-deoxy-fluoro-1-*O*-(*p*-methoxybenzyl)-[*myo*-inositol]

myo/scyllo-inositol 4,5-bis-*O*-dibenzylphosphate

25 To a mixture of 1D-3,6-di-*O*-benzyl-2-deoxy-fluoro-1-*O*-(*p*-methoxybenzyl)-[*myo*-inositol] *myo/scyllo*-inositol (375 mg, 0.78 mmol) and 1H-tetrazole (358 mg, 5.11 mmol) in 5 ml dry CH₂Cl₂ was added *N,N*-diisopropyl dibenzyl phosphoramidite (0.87 ml, 2.6 mmol). The reaction mixture was stirred at r.t. for 10 min. The TLC in CHCl₃-diethyl ether (80:20) showed no starting material left (*R*_f = 0.175). The mixture was
30 cooled down to -50°C (CHCl₃/liq.N₂) and 3-chloroperoxybenzoic acid (60-80% purity,

877 mg, 3.0 mmol) in 10 ml dry CH₂Cl₂ was added. The resulting solution was stirred at 0°C for 15 min. The reaction mixture was diluted with 50 ml CH₂Cl₂, 100 ml 20 % Na₂SO₃ solution was added and stirred at r.t. for 1 hr (until a negative NaI reaction for peroxides is shown). Organic layer was washed with 3x50 ml sat. NaHCO₃ solution; 2x20 ml water and 2x25 ml sat. NaCl solution. Combined organic extracts were dried over Na₂SO₄, filtered and solvent evaporated. Crude reaction product was chromatographed on Silicagel 60Å eluting with a gradient of CHCl₃/diethyl ether (99:1 to 95:5) giving pure 1D-3,6-di-*O*-benzyl-2-deoxy-fluoro-1-*O*-(*p*-methoxybenzyl)-[*myo*-inositol] *myo/scyllo*-inositol 4,5-bis-*O*-dibenzylphosphate: 702.5 mg (90.1%). [α]_D²⁰ -15.03° (c 0.9, CHCl₃) MALDI TDF MS m/z, ¹H NMR (300 MHz, CDCl₃) δ ppm 1.02-1.34 (dd, 5H), 2.04-2.3 (s, 1H), 3.38-3.9 {m,s, 8H [3.35 (t, 2H)], 3.45 (m, 2H), 3.65 (m, 1H), 3.8 (s, 3H)}, 4.4-4.6 (m, 1H), 4.7-5.3 (m, 14H), 6.6-6.9 (m, 2H), 7.0-7.5 (m, 32H).

1D-3,6-di-*O*-benzyl-2-deoxy-fluoro-[*scyllo*-inositol] *myo/scyllo*-inositol
4,5-bis-*O*-dibenzylphosphate

To a 0°C solution of 1D-3,6-di-*O*-benzyl-2-deoxy-fluoro-1-*O*-(*p*-methoxybenzyl)-[*myo*-inositol] *myo/scyllo*-inositol 4,5-bis-*O*-dibenzylphosphate (600 mg, 0.5986 mmol) in 6 ml CH₂Cl₂-H₂O (20:1) was added solid 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (540 mg, 2.36 mmol). After 2 hr. the reaction mixture was diluted with cold sat. NaHCO₃ solution (200 ml) and extracted with CH₂Cl₂ (4x50 ml). The combined organic extracts were washed with brine, dried over Na₂SO₄, evaporated and the residue purified by column chromatography on Silicagel 60Å with gradient elution with CHCl₃-diethyl ether to give 1D-3,6-di-*O*-benzyl-2-deoxy-fluoro-[*scyllo*-inositol] *myo/scyllo*-inositol 4,5-bis-*O*-dibenzylphosphate: 387.2 mg (73.3 %). [α]_D²⁰ -12.2° (c 0.98, CHCl₃) MALDI TDF MS m/z 906.0, calc. (M+Na)⁺ 905.85. ¹H-NMR (300 MHz, CDCl₃) δ ppm 1.2 (s, 2H), 1.56 (s, 6H), 2.78 (s, 1/2H), 3.38 (ψt, J 1H), 3.35 (m, 1H), 3.77 (m, 1H), 4.45-4.58 (m, 4H), 4.6-5.1 (m, 10H), 5.24 (s, 8H), 7.75 (m, 30H).

1D-3,6-di-*O*-benzyl-1-*O*-(1',2'-*O*-dibutyl-*sn*-glycero-3'-phospho)-

2-deoxy-fluoro-[*myo*-inositol] *myo/scyllo*-inositol 4,5-bis-*O*-dibenzylphosphate

To a solution of 1D-3,6-di-*O*-benzyl-2-deoxy-fluoro-[*scyllo*-inositol] *myo/scyllo*-inositol 4,5-bis-*O*-dibenzylphosphate of 41.1 mg (0.0466 mmol) (dried excessively over P₂O₅) in dry pyridine was added triisopropyl-benzene sulphonyl chloride 100 mg (0.33 mmol). After stirring for 15 mins. at r.t. 1,2-dibutyl-*sn*-glycero-3-phosphate(phosphatidic acid) 34.1 mg (0.12 mmol) was added. After 10 hr. at r.t. reaction mixture was hydrolyzed by diluting with CH₂Cl₂-H₂O (20:1) and leaving at r.t. overnight. After evaporating the solvents to dryness the residue was extracted with anhydrous diethyl ether, which gave the crude reaction product. Purification on Silicagel 60Å with gradient elution with CHCl₃-triethylamine and subsequent chromatography eluting with CHCl₃-CH₃OH-NH₄OH gave the product: 11.5 mg, 21.5%. [α]_D²⁰ +6.22° (c 0.94, CHCl₃) MALDI TDF MS m/z ; ¹H NMR (300 MHz, D₂O) δppm 0.7-0.8 (br, 3H), 0.95-1.03 (m, 15H), 1.1-1.3 (br, 3H), 1.35-1.5 (ψt, 3H), 2.55 (s, 3H), 2.8-3.0 (d, 1H), 3.3-3.45 (m, 10 or 15H), 3.5-3.66 (m, 3H), 3.7-3.85 (m, 3H), 3.9-4.1 (br, 1H), 4.15-4.3 (br, 1H), 4.35-4.4 (br, 1H), 4.65 (s,); ¹H NMR (300mhz, DMSO) δppm 0.8-0.9 (br, 2H), 1.0-1.1 (m, 5H), 1.12-1.18 (t, 3H), 1.2-1.35 (ψt, 6H), 2.08 (s, 1H), 2.35 (s,), 2.4-2.6 (br,), 2.65 (s,), 2.9-3.2 (dd, 7H), 4.35 (t, 1H), 6.9-7.26 (ψt, 5H).

1D-3,6-Di-*O*-benzyl-2-deoxy-fluoro-1-*O*-(1', 2'-di-*O*-palmitoyl-*sn*-glycero-3'-*O*-phospho)-[*scyllo*-inositol] *myo/scyllo*-inositol 4,5-bis-*O*-dibenzylphosphate

To a solution of 1D-3,6-di-*O*-benzyl-2-deoxy-fluoro-*scyllo*-inositol 4,5-bis-*O*-dibenzylphosphate (20.8mg, 0.0236mmol) in 0.2ml of dry pyridine was added triisopropyl-benzene sulphonyl chloride (15mg, 0.0472mmol). After stirring for 10 mins at r.t., 1,2-dipalmitoyl-*sn*-3-glycerophosphate (Na salt, 16.5mg, 0.0246mmol) was added. After 10 hrs at r.t. reaction mixture was diluted with 2ml ethanol-free CHCl₃ and stirring at r.t. for another 3-4hrs. Water (1ml) was added and solvents were removed on a rotary evaporator. The dry residue was extracted with anhydrous diethyl ether (3x5ml), filtered and the ether was evaporated. The crude product was chromatographed on silicagel 60Å eluting with a gradient of CHCl₃-MeOH-NH₄OH (99:1:0.1 to 80:20:2) to afford pure 1D-

3,6-di-*O*-benzyl-2-deoxy-fluoro-1-*O*-(1', 2'-di-*O*-palmitoyl-*sn*-glycero-3'-*O*-phospho)-*myo*-inositol 4,5-bis-*O*-dibenzylphosphate: 10.2mg, 28.6%. $[\alpha]_{589} +10.8^{\circ}$ (c 0.5, CHCl₃)
MALDI TDF MS m/z, ¹H NMR: δ ppm 0.6-1.0 (m, 5H), 1.0-1.4 (s, 2H), 2.2 (br, 4H), 4.0 (br, 1H), 4.4-5.0 (br, 5H), 5.3 (s, 1H), 6.9-7.5 (m, 12H).

5

1D-2-deoxy-fluoro-1-*O*-(1', 2'-di-*O*-palmitoyl-*sn*-glycero-3'-*O*-phospho)-*myo*-inositol 4,5-bis-*O*-phosphate

1D-3,6-di-*O*-benzyl-2-deoxy-fluoro-1-*O*-(1', 2'-di-*O*-palmitoyl-*sn*-glycero-3'-*O*-phospho)-*myo*-inositol 4,5-bis-*O*-dibenzylphosphate (5.5mg, 0.0036mmol) in 2ml
10 ethanol and 0.5ml CHCl₃ was hydrogenated for 6hrs using 10mg Pd-black and H₂ gas at 45psi. After filtering the catalyst and evaporating the solvent, 1D-2-deoxy-fluoro-1-*O*-(1', 2'-di-*O*-palmitoyl-*sn*-glycero-3'-*O*-phospho)-*myo*-inositol 4,5-bis-*O*-phosphate (2.4mg, 67.8%) was obtained. ¹H NMR (300MHz, DMSO-d₆) δ ppm: 0.8-0.9 (m, 10H), 1.0-1.1 (m, 16H), 1.15-1.4 (br, 60H), 1.5-1.6 (ψ , t, 4H), 2.1-2.3 (d, t, 2H), 2.35 (ψ t, 1H),
15 2.45-2.55? 2.55-2.6 (t, 4H), 2.6-2.66 (t, 1H), 2.68-2.74 (m, 4H), 2.88 (s, 1H), 3.34-3.42 (m, 18H), 3.5 (d, 1H), 3.98-4.06 (m, 4H), 4.1-4.18 (t, 1H), 5.1 (s, 1H), 7.8 (m, 1H).

1D-2,3,6-Tri-*O*-benzyl-1-(*p*-methoxybenzyl)-*myo*-inositol

[1D-3,6-Di-*O*-benzyl-4,5-di-*O*-cyclohexylidene-1-(*p*-methoxybenzyl)-*myo*-inositol]

20 1D-3,6-Di-*O*-benzyl-4,5-*O*-cyclohexylidene-1-(*p*-methoxybenzyl)-*myo*-inositol (29mg, 0.052mmol) was treated with 1.5ml DMF, 2mg (0.05mmol) NaH (60%, in oil) and 6 μ l (0.05mmol) benzyl bromide at 0-5^oC. TLC (hexane-ethyl acetate 70:30) showed reaction was over. Excess NaH was destroyed by adding DH₂O at 0-5^oC. DMF and water were evaporated. Residue was extracted, evaporated to dryness.

25 To the crude material, 100 μ l CH₂Cl₂, 20 μ l of *p*-toluenesulfonic acid solution (dissolved in ethylene glycol, 140mg/4ml) were added. Reaction was stirred at r.t. for several hours. TLC (CHCl₃-MeOH 95:5) showed conversion was finished. Two drops of triethylamine was added. Reaction was diluted, extracted, dried and concentrated. Column chromatography of the crude material eluted with a mixture of CHCl₃-MeOH gave pure 1D-2,3,6-tri-*O*-benzyl-1-(*p*-
30 methoxybenzyl)-*myo*-inositol. 21mg, 70%, $[\alpha]_{\text{D}} +10.79^{\circ}$ (c 1.39, CHCl₃).

1D-2,3,6-Tri-*O*-benzyl-1-*O*-(*p*-methoxybenzyl)-*myo*-inositol 4,5-bis-*O*-dibenzylphosphate

To a solution of 1D-2,3,6-tri-*O*-benzyl-1-*O*-(*p*-methoxybenzyl)-*myo*-inositol (26.7mg, 0.0468mmol) in 2ml CH₂Cl₂ (dried over P₂O₅), 1H tetrazole (26.25mg, 0.37mmol) and N,N-diisopropyldibenzylphosphoramidite (26.25mg, 0.37mmol) were added. Solution was stirred at r.t. for 30 mins. 3-chloroperoxybenzoic acid (71.1mg, 0.41mmol) was added at -40°C. Reaction was stirred at 0-5°C for 15 mins. TLC (hexane-ethyl acetate 60:40) showed reaction was over. 20ml 20% Na₂SO₃ solution was added, reaction was stirred for 1/2 hour. NaI test was checked (negative). Reaction was then extracted with CH₂Cl₂, washed with saturated NaHCO₃ solution, followed by saturated NaCl solution. CH₂Cl₂ layer was dried and concentrated. Column chromatography of the crude material eluted with a gradient of hexane-CH₂Cl₂-ethyl acetate gave pure 1D-2,3,6-tri-*O*-benzyl-1-*O*-(*p*-methoxybenzyl)-*myo*-inositol 4,5-bis-*O*-dibenzylphosphate. 37mg, 70% [α]_D -9.37° (c 1.03, CHCl₃).

15 1D-2,3,6-Tri-*O*-benzyl-*myo*-inositol 4,5-bis-*O*-dibenzylphosphate

A mixture of 1D-2,3,6-tri-*O*-benzyl-1-*O*-(*p*-methoxybenzyl)-*myo*-inositol 4,5-bis-*O*-dibenzylphosphate (30mg, 0.026mmol), 1.5ml CH₂Cl₂, 1 drop of DH₂O and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (12.5mg, 0.055mmol) was stirred at r.t. for 15 mins. TLC (hexane-ethyl-acetate 50:50) showed reaction was complete. Solution was then extracted, washed with cold saturated NaHCO₃ solution, followed by cold saturated NaCl solution. CH₂Cl₂ layer was dried and concentrated. Column chromatography of the crude material eluted with a gradient of hexane-CH₂Cl₂-ethyl acetate gave pure 1D-2,3,6-Tri-*O*-benzyl-*myo*-inositol 4,5-bis-*O*-dibenzylphosphate. 22mg, 85% [α]_D = -11.01° (c 0.99, CHCl₃).

25 ω -Cbz-aminobutanoic acid

N-aminobutanoic acid (5.06g, 0.05mol) was treated with benzyl chloroformate (7.8ml 0.055mol) and NaOH solution (2g in 50ml DH₂O) alternatingly at 0-5°C in 1 hr. Mixture was stirred at r.t. for 48 hrs. Reaction was extracted with CHCl₃ 4x30ml. Aqueous layer was acidified to PH \approx 2-3. An oil precipitated and quickly solidified. White solid was filtered out, washed with water several times and dried on a funnel. White precipitates was then dissolved in CH₂Cl₂,

filtered, dried over Na_2SO_4 , filtered one more time and evaporated to dryness. 8.98g, 75%, m.p.: 63-65°C.

1-O-Hexanoyl-2-O-(ω -Cbz-aminobutanoyl)-sn-glycero-3-phosphocholine

5 Preparation of anhydride: dicyclohexylcarbodi-imide (1.6128g, 7.82mmol) was dissolved in 10ml dry CCl_4 ; ω -Cbz-aminobutanoic acid (3.384g, 14.26mmol) was dissolved in a mixture of CCl_4 (25ml) and CH_2Cl_2 (20ml). Dicyclohexylcarbodi-imide solution was pipetted to the ω -Cbz-aminobutanoic acid solution. Mixture was stirred at r.t. for 1 hr until white precipitate appeared and was filtered. Esterification: 1-*O*-hexanoyl-*sn*-glycero-3-phosphocholine (1.0114g, 2.85mmol)
10 was dissolved in dry CHCl_3 (20ml), dimethylaminopyridine (0.426g, 2.85mmol) was added, followed by the anhydride solution prepared earlier. The solution was stirred for a short while before adding dicyclohexylcarbodi-imide (0.654g, 3.17mmol) in CCl_4 (5ml). Mixture was stirred at r.t. for 48 hrs. Reaction was then filtered, precipitates were washed with less than 1ml CCl_4 . Solvents were evaporated, resulting viscous colorless residue was purified by chromatography on
15 silicagel eluted with CHCl_3 -MeOH gave 1-*O*-hexanoyl-2-*O*-(ω -Cbz-aminobutanoyl)-*sn*-glycero-3-phosphocholine. 1.3g, 80%.

1-O-Hexanoyl-2-O-(ω -Cbz-aminobutanoyl)-sn-glycero-3-phosphoric acid

1-*O*-hexanoyl-2-*O*-(ω -Cbz-aminobutanoyl)-*sn*-glycero-3-phosphocholine (0.8063g,
20 1.4mmol) in 15ml acetate buffer (PH = 5.6) was sonicated. 100ml acetate buffer, phospholipase D (4mg) and ethanol free ether were added. Mixture was stirred vigorously for 1.5 hrs at 37°C and white precipitates formed. To the cold (0-5°C) reaction, a cold solution of CHCl_3 (140ml), MeOH (280ml) and concentrated HCl (1.2ml) was added. Reaction was mixed well and aqueous layer was extracted with cold CHCl_3 7x50ml. Combined organic layer was filtered and evaporated to
25 dryness. 0.68g, 100%.

*1D-1-[1'-O-Hexanoyl-2'-O-(ω -Cbz-aminobutanoyl)-sn-glycero-3'-phospho]-
3,6-di-O-benzyl-myo-inositol-4,5-bis-O-dibenzylphosphate*

To a solution of 1D-3,6-di-*O*-benzyl-*myo*-inositol-4,5-bis-*O*-dibenzylphosphate
30 (33.5mg, 0.038mmol) (dried excessively over P_2O_5) in dry pyridine was added

triisopropyl-benzene sulphonyl chloride (34.7mg, 0.114mmol). After stirring for 15 mins. at r.t., 1-*O*-hexanoyl-2-*O*-(ω -Cbz-aminobutanoyl)-*sn*-glycero-3-phosphocholine (36.2mg, 0.076mmol) was added. After 10 hrs. at r.t. reaction mixture was hydrolyzed by diluting with CH₂Cl₂-H₂O (20:1) and leaving at r.t. overnight. After evaporating the solvents to dryness the residue was extracted with anhydrous diethyl ether, which gave the crude reaction product. Purification on Silicagel with gradient elution with CHCl₃-triethylamine and subsequent chromatography eluting with CHCl₃-CH₃OH-NH₄OH gave 1D-1-[1'-*O*-hexanoyl-2'-*O*-(ω -Cbz-aminobutanoyl)-*sn*-glycero-3'-phospho]-3,6-di-*O*-benzyl-*myo*-inositol-4,5-bis-*O*-dibenzylphosphate: 24.7mg, 48%.

1D-1-[1'-*O*-Hexanoyl-2'-*O*-(ω -aminobutanoyl)-*sn*-glycero-3'-phospho]-
myo-inositol-4,5-bis-*O*-phosphate

1D-1-[1'-*O*-hexanoyl-2'-*O*-(ω -Cbz-aminobutanoyl)-*sn*-glycero-3'-phospho]-3,6-di-*O*-benzyl-*myo*-inositol-4,5-bis-*O*-dibenzylphosphate (24.7mg, 0.018mmol) was hydrogenated and recovered and characterized as described for 1D-2-deoxy-fluoro-1-*O*-(1',2'-di-*O*-palmitoyl-*sn*-glycero-3'-*O*-phospho)-*myo*-inositol 4,5-bis-*O*-phosphate.

LITERATURE CITED

Aneja R. (1974) *Biochem. Soc. Trans.*, 2, 38-41.

- 5 S. G. Aneja, A. Parra, C. Stoenescu, W. Xia and R. Aneja (1997) *Tetrahedron Lett.*, 38, 803-806.

Auger K.R., Serunian L.A., Soltoff S.P., Libby P., Cantley L.C. (1989) *Cell*, 57, 167-175.

Berridge M.J. (1984) *Biochem. J.*, 220, 345.

10

Bruzik K.S. and Tsai, M-D. (1994) *Bioorg. Med. Chem.* 2, 49-72.

Carpenter C.L. and Cantley, L.C. (1990) *Biochemistry*, 29, 11147-56.

- 15 Carpenter C.L. and Cantley, L.C. (1996) *Biochim. Biophys. Acta*, 1288, M11-M16.

Carpenter, C.L. and Cantley, L.C. *Current Opinion in Cell Biology* 1996, 8, 153-158.

Chen J., Profit A.A. and Prestwich G.D. (1996) *J. Org. Chem.* 61, 6305-6312.

20

Coughlin S.R., Escobedo J.A., Williams, L.T. (1989) *Science*, 243, 1191-94.

Essen L-O, Perisic O., Cheung R., Katan M. and Williams, R.L. (1996) *Nature*, 380, 595-602.

- 25 Essen L-O, Perisic O., Katan M., Wu, Y., Roberts, M.F. and Williams, R.L. (1997) *Biochemistry*, 36, 1704-1718.

Gadella T.W.J., Moritz A., Westerman J., and Wirtz K.W.A. (1990) *Biochemistry*, 29, 3389-3395.

Grobler J.A. and Hurley J.H. (1996) *Protein Science* 5, 680-686.

30

Gu Q.M. and Prestwich G.D. (1996) J. Org. Chem. 61, 8642-8647.

Heinz D.W., Ryan M., Bullock T.L., Griffith O.H. (1995) The EMBO J. 14, 3855-3863.

- 5 Hendrickson H.S., Hendrickson E.K., Johnson J.L., Khan T.H., and Chial H.J. (1992) Biochemistry, 31, 12169-12172.

Kozikowski A.P, U.S. Pat. No. 5,053,399

- 10 Kozikowski A.P., Faug A.H. and Powis G. (1993) U.S. Pat. No. 5,227,508.

Lin G., Bennett F., and Tsai M-D. (1990) Biochemistry, 29, 2747-2757.

Majerus P.W. (1992) Annu. Rev. Biochem., 61, 225-250.

15

Nishizuka Y. (1983) Trends in Biochem. Sc., 8, 13.

Serunian L.A., Haber M.T., Fukui T., Kim J.W., Rhee S.G., Lowenstein J.M., and Cantley, L. (1989) J. Biol. Chem., 264, 17809-17815.

20

Shashidhar M.S., Volwerk J.J., Griffith O.H., and Keana F.W., (1991) Chem. Phys. Lipids, 60, 101-110.

Volwerk J.J., Shashidhar M.S., Kuppe A., and Griffith O.H. (1990) Biochemistry, 29, 8056-8060.

25

Whitman M., Downes C.P., Keeler M., Keller T., Cantley L. (1988) Nature, 332, 644-46.

Yang S.S., Beattie T.R., Durette P.L., Gallagher T.F. and Shen T-Y. (1985) U.S. Pat. No. 4,515,722).

30

ABSTRACT

This invention provides analogues of phosphatidylinositol-phosphates modified at one or more selected inositol-hydroxyls and optionally carrying reporter or anchoring groups attached in the lipid or the inositol residues, and, the synthetic intermediates and methods for the preparation of these analogues. The analogues are useful as research reagents in biomedical studies related to structure, function and therapeutics, including reference materials for analyzing the metabolic products in safety and efficacy studies of 2- and/or 3-hydroxyl modified inositols and phosphatidylinositols as drug candidates.